Searched for
ABATACEPT
Dr Reddy's Q3 preview: PAT may fall 22% YoY as US pressure to weigh on earningsDr Reddy's Laboratories anticipates a subdued performance for the December quarter. Pressure from its United States business is expected to...20 Jan, 2026, 12.46 PM IST- Dr Reddy’s Laboratories shares fall over 1% on Q2 results. Should you buy, sell or hold?Despite an uptick in profits, Dr Reddy's Laboratories experienced a decline in share value. Analysts continue to express optimism, keeping ...27 Oct, 2025, 09.28 AM IST
- Can DRL’s new product launches offset the slowdown in Revlimid sales?Dr Reddy's Laboratories saw a high single-digit revenue increase in Q3, driven by India, emerging, and European markets, despite a muted US...27 Oct, 2025, 05.59 AM IST
- Dr Reddy's Laboratories Q2 Results: Profit rises 7% YoY to Rs 1,347 crore, revenue up 10%Dr Reddy's Laboratories Q2 Results: Generic drugmaker Dr Reddy's Labs reported 7% growth in its net profit at Rs 1,347 crore in the Septemb...24 Oct, 2025, 05.34 PM IST
- Buy, Sell or Hold: Antique maintains Hold on Infosys; Nuvama maintains Buy on Dr Reddy’s LaboratoriesBrokerages shared mixed views on key Indian stocks. Antique maintained a ‘Hold’ on Infosys citing margin concerns, while Nuvama stayed bull...24 Jul, 2025, 09.24 AM IST
- Dr. Reddy's Laboratories shares jump 2% as Q1 net profit jumps 2% YoY. Should you invest?Dr. Reddy's Laboratories shares: The company reported operational revenue of ₹8,545 crore, reflecting a solid 11% year-on-year increase. Ho...24 Jul, 2025, 09.22 AM IST
- DRL gears up for biosimilar push, consumer health growth post record FY25Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launc...20 May, 2025, 05.59 AM IST
- JM Financial maintains Buy on Dr. Reddy's Laboratories, lowers target price to Rs 1418JM Financial maintains a Buy call on Dr. Reddy's Laboratories, revising the target price to Rs 1,418. The brokerage anticipates strong FY26...14 May, 2025, 08.51 AM IST
- Stocks to buy today: MOSL upgrades Aurobindo Pharma to buy; Nuvama sees over 30% upside in DRLChoice Broking maintains a positive outlook on Mahindra & Mahindra (M&M), citing its dominant position in the SUV and tractor markets and r...12 May, 2025, 10.28 AM IST
- Dr Reddy's shares rally 4% as Nuvama upgrades rating to buyDr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the impact of Re...08 Jan, 2025, 11.33 AM IST
- Dr Reddy's Labs shares up 3% after Q2 results. What should investors do?Dr. Reddy's Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While analysts acknowled...06 Nov, 2024, 09.51 AM IST
- Dr Reddy's Labs Q2 Preview: Healthy double-digit revenue growth seen, but PAT may fallAnalysts project U.S. revenue at $419 million, supported by a strong contribution from gRevlimid. The India business is expected to grow 19...05 Nov, 2024, 08.39 AM IST
- Stocks in the news: CEAT, HDFC AMC, RBL Bank and Adani PortsAdani Group said that its engagement with financial institutions over a petrochemical project at Mundra in Gujarat was still ongoing. The g...21 Mar, 2023, 07.15 AM IST
- Dr Reddy's Laboratories planning mergers and acquisitions to climb up ladderIndia contributed about a fifth or ₹4,196 crore of the company's overall sales of ₹21,439 crore in 2021-22, but domestic business has clock...24 Jun, 2022, 03.54 PM IST
- How Dr Reddy’s is rebooting its biosimilars playDr Reddy’s was among the first to race off the blocks with four launches in India about as many years. But things have slowed since.29 Sep, 2015, 02.51 AM IST
Load More
